Castle biosciences announces prospective, multi-center publication demonstrating decisiondx®-melanoma as significant, independent predictor of patient outcomes in cutaneous melanoma

Friendswood, texas--(business wire)---- $cstl #melanoma--castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of prospective, multi-center long-term outcomes data in cutaneous melanoma as impacted by decisiondx®-melanoma. decisiondx-melanoma is castle's gene expression profile test that uses an individual patient's tumor biology to predict risk of cutaneous melanoma metastasis or
CSTL Ratings Summary
CSTL Quant Ranking